PMID- 34196124 OWN - NLM STAT- MEDLINE DCOM- 20220425 LR - 20220425 IS - 2573-8348 (Electronic) IS - 2573-8348 (Linking) VI - 5 IP - 3 DP - 2022 Mar TI - Real-world experience of nivolumab in the treatment of poor performance status patients with advanced non-small cell lung cancer. PG - e1487 LID - 10.1002/cnr2.1487 [doi] LID - e1487 AB - BACKGROUND: Nivolumab improves disease control and survival in advanced NSCLC in patients with good performance status (PS), but there is limited data on its efficacy in patients with poor PS. AIM: Primary objective of the study was to evaluate the efficacy and safety of nivolumab and examine the influence of PS on outcomes. METHODS AND RESULTS: Retrospective analysis of patients treated with single-agent nivolumab for advanced NSCLC at a single institution was performed. Sixty-six patients treated with nivolumab were identified (33 male) with a median age of 68.5 years. Fifty-six (85%) patients were current or former smokers and 17 (26%) had brain metastasis. All patients had received prior chemotherapy, 39 (59%) patients received one and 27 (41%) had >/=2 prior lines of therapy. Median overall survival (OS) was 7.1 months (95%CI 3.61-11.3) in the overall study population. OS of patients with PS >/=2 at the start of treatment was 3.04 months (95%CI 1.64-7.36) as compared to 10.23 months (95%CI 7.06-18.9) with PS /=2 at the start of treatment and 2 (8%) of these patients developed a partial response, 4 (15%) had stable disease; the overall disease control rate was 23%. Fourteen (58%) patients with PS >/=2 had disease progression at the time of first disease response evaluation. In the overall population, 20% of patients experienced grade >/=3 treatment-related adverse events (TRAEs), most commonly pneumonitis, hepatitis, and colitis. Fourteen TRAEs led to treatment discontinuation, 9 (23%) adverse events (AEs) in patients with PS /=2. Fourteen (21%) patients died within 30 days of the last nivolumab treatment. CONCLUSION: There was no significant difference in toxicity leading to treatment discontinuation between the poor and good PS groups, but survival was shorter with poorer PS. PS appears to be an important prognostic factor and remains a relevant discriminator in the selection of treatment with immunotherapy for lung cancer. CI - (c) 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. FAU - Abbas, M Nazim AU - Abbas MN AUID- ORCID: 0000-0002-1562-3708 AD - Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia. AD - College of Medicine and Public Health, Flinders University, Adelaide, Australia. FAU - Klevansky, Myron AU - Klevansky M AD - Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia. FAU - Koczwara, Bogda AU - Koczwara B AD - Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia. AD - College of Medicine and Public Health, Flinders University, Adelaide, Australia. FAU - Roy, Amitesh Chandra AU - Roy AC AD - Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia. AD - College of Medicine and Public Health, Flinders University, Adelaide, Australia. FAU - Sukumaran, Shawgi AU - Sukumaran S AD - Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia. AD - College of Medicine and Public Health, Flinders University, Adelaide, Australia. FAU - Vatandoust, Sina AU - Vatandoust S AD - Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia. AD - College of Medicine and Public Health, Flinders University, Adelaide, Australia. FAU - Karapetis, Christos Stelios AU - Karapetis CS AD - Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia. AD - College of Medicine and Public Health, Flinders University, Adelaide, Australia. LA - eng PT - Journal Article DEP - 20210630 PL - United States TA - Cancer Rep (Hoboken) JT - Cancer reports (Hoboken, N.J.) JID - 101747728 RN - 31YO63LBSN (Nivolumab) SB - IM MH - Aged MH - *Carcinoma, Non-Small-Cell Lung MH - Female MH - Humans MH - Immunotherapy MH - *Lung Neoplasms MH - Male MH - Nivolumab/adverse effects MH - Retrospective Studies PMC - PMC8955060 OTO - NOTNLM OT - nivolumab OT - non-small cell lung cancer OT - performance status OT - real-world COIS- Christos Stelios Karapetis has served on the advisory board for BMS, ROCHE, and AstraZeneca. The rest of the authors have no disclosures and declare to have no conflicts of interest concerning this manuscript. EDAT- 2021/07/02 06:00 MHDA- 2022/04/26 06:00 PMCR- 2021/06/30 CRDT- 2021/07/01 07:32 PHST- 2021/05/14 00:00 [revised] PHST- 2020/12/21 00:00 [received] PHST- 2021/06/14 00:00 [accepted] PHST- 2021/07/02 06:00 [pubmed] PHST- 2022/04/26 06:00 [medline] PHST- 2021/07/01 07:32 [entrez] PHST- 2021/06/30 00:00 [pmc-release] AID - CNR21487 [pii] AID - 10.1002/cnr2.1487 [doi] PST - ppublish SO - Cancer Rep (Hoboken). 2022 Mar;5(3):e1487. doi: 10.1002/cnr2.1487. Epub 2021 Jun 30.